AMS has performed poorly in relation to the S&P 500, but a turnaround may be in progress, judging by the last three months price action. Recent earnings have been good and the stock looks cheap. There is a 3.07% dividend yield and the company has definite growth potential. In addition, there has been insider buying activity in the last three months.
AMS and its subsidiaries provide Gamma Knife stereotactic radiosurgery services to medical centers in the United States. The Gamma Knife is a noninvasive treatment for brain tumors, vascular malformations, and trigeminal neuralgia. The company provides the Gamma Knife equipment, as well as planning, installation, reimbursement, and marketing support services to 21 medical centers in 18 states.
AMS also offers “The Operating Room for the 21st Century”, state-of-the-art surgical suites, at major medical centers on a fee-for-use or other shared basis. These operating rooms incorporate diagnostic imaging equipment to guide surgical procedures, with computer-controlled navigation systems an integral component. Robotic technology is included to provide assistance to the surgeon. The suite includes a computer-controlled, motorized combination operating room table and ICU bed with on-board sensors and dispensers for oxygen, anesthetic gases and intravenous fluids.